According to the Securities Times, AI pharmaceuticals have recently attracted market attention due to frequent project cooperation and investment and financing events. The reporter learned from the industry that as AI accelerates its penetration into the pharmaceutical industry, the research and development of innovative drugs has ushered in a milestone progress, and the results of AI pharmaceuticals have blossomed in many places. At the same time, AI pharmaceuticals are facing commercial difficulties, and it will take time to solve them. Recently, large orders in the field of AI pharmaceuticals have frequently appeared. On June 11, Novo Nordisk reached a US$812 million cooperation with AI pharmaceutical company Deep Apple Therapeutics; on June 12, Eli Lilly and Juvena Therapeutics (an American AI pharmaceutical company) signed an agreement of more than US$650 million; on June 13, AstraZeneca (AZ) and Shijiazhuang Pharmaceutical Group reached a cooperation of up to US$5.3 billion to use Shijiazhuang Pharmaceutical Group's AI drug discovery platform to develop small molecule drug candidates. On June 23, Jingtai Holdings, a leading domestic AI pharmaceutical company, signed a multi-billion dollar pipeline licensing cooperation letter of intent with DoveTree LLC (a company founded by Gregory Verdine, a legendary entrepreneur and investor in the US pharmaceutical industry); on the same day, AI pharmaceutical company Formation Bio announced that its subsidiary had licensed the oral dual JAK/SYK inhibitor gusacitinib to Sanofi, with the maximum cooperation amount reaching 545 million euros. In less than a month, nearly 10 billion US dollars flowed into the AI pharmaceutical industry, causing a stir in the industry.